.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AA03_Ethinylestradiol.Ethinylestradiol .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AA03_Ethinylestradiol.Ethinylestradiol| name: | Ethinylestradiol |
| ATC code: | L02AA03 | route: | oral |
| n-compartments | 1 |
Ethinylestradiol is a synthetic derivative of estradiol, used primarily as an oral contraceptive in combination with progestins. It is widely used for birth control and in hormone replacement therapy. Ethinylestradiol is an approved and commonly prescribed medication today.
Pharmacokinetic parameters reported in healthy adult women after single oral dose.
Mohamed, MF, et al., & Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. Journal of clinical pharmacology 59(4) 510–516. DOI:10.1002/jcph.1350 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30500075
Kiriwat, O, & Fotherby, K (1983). Pharmacokinetics of oral contraceptive steroids after morning or evening administration. Contraception 27(2) 153–160. DOI:10.1016/0010-7824(83)90086-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/6851554
Ezuruike, U, et al., & Rowland Yeo, K (2018). Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. Clinical pharmacology and therapeutics 104(6) 1229–1239. DOI:10.1002/cpt.1085 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29637542